HK1255481A1 - 用於治療hcv的方法 - Google Patents
用於治療hcv的方法Info
- Publication number
- HK1255481A1 HK1255481A1 HK18114657.5A HK18114657A HK1255481A1 HK 1255481 A1 HK1255481 A1 HK 1255481A1 HK 18114657 A HK18114657 A HK 18114657A HK 1255481 A1 HK1255481 A1 HK 1255481A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- methods
- treating hcv
- hcv
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06F—ELECTRIC DIGITAL DATA PROCESSING
- G06F16/00—Information retrieval; Database structures therefor; File system structures therefor
- G06F16/20—Information retrieval; Database structures therefor; File system structures therefor of structured data, e.g. relational data
- G06F16/21—Design, administration or maintenance of databases
- G06F16/215—Improving data quality; Data cleansing, e.g. de-duplication, removing invalid entries or correcting typographical errors
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06F—ELECTRIC DIGITAL DATA PROCESSING
- G06F16/00—Information retrieval; Database structures therefor; File system structures therefor
- G06F16/20—Information retrieval; Database structures therefor; File system structures therefor of structured data, e.g. relational data
- G06F16/23—Updating
- G06F16/2365—Ensuring data consistency and integrity
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06F—ELECTRIC DIGITAL DATA PROCESSING
- G06F16/00—Information retrieval; Database structures therefor; File system structures therefor
- G06F16/20—Information retrieval; Database structures therefor; File system structures therefor of structured data, e.g. relational data
- G06F16/23—Updating
- G06F16/2379—Updates performed during online database operations; commit processing
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06F—ELECTRIC DIGITAL DATA PROCESSING
- G06F7/00—Methods or arrangements for processing data by operating upon the order or content of the data handled
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06F—ELECTRIC DIGITAL DATA PROCESSING
- G06F16/00—Information retrieval; Database structures therefor; File system structures therefor
- G06F16/20—Information retrieval; Database structures therefor; File system structures therefor of structured data, e.g. relational data
- G06F16/25—Integrating or interfacing systems involving database management systems
- G06F16/252—Integrating or interfacing systems involving database management systems between a Database Management System and a front-end application
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Theoretical Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Databases & Information Systems (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Data Mining & Analysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Quality & Reliability (AREA)
- Computer Security & Cryptography (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562190045P | 2015-07-08 | 2015-07-08 | |
US201562266954P | 2015-12-14 | 2015-12-14 | |
PCT/US2016/041334 WO2017007934A1 (en) | 2015-07-08 | 2016-07-07 | Methods for treating hcv |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1255481A1 true HK1255481A1 (zh) | 2019-08-16 |
Family
ID=56497883
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18114657.5A HK1255481A1 (zh) | 2015-07-08 | 2018-11-15 | 用於治療hcv的方法 |
Country Status (10)
Country | Link |
---|---|
US (2) | US20180177779A1 (zh) |
EP (1) | EP3319604A1 (zh) |
JP (2) | JP6808660B2 (zh) |
CN (1) | CN107921038A (zh) |
AU (1) | AU2016291154B2 (zh) |
BR (1) | BR112018000383A2 (zh) |
CA (1) | CA2991417A1 (zh) |
HK (1) | HK1255481A1 (zh) |
MX (1) | MX2018000240A (zh) |
WO (1) | WO2017007934A1 (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
CN110302361A (zh) | 2014-04-02 | 2019-10-08 | 艾伯维公司 | 治疗hcv的方法 |
US20170248953A1 (en) * | 2016-02-25 | 2017-08-31 | Ford Global Technologies, Llc | Autonomous peril control |
JP2018131439A (ja) * | 2017-02-14 | 2018-08-23 | アッヴィ・インコーポレイテッド | Hcvを処置する方法 |
CA2981993A1 (en) * | 2017-08-02 | 2019-02-02 | Abbvie Inc. | Methods for treating hcv |
EP3883569A1 (en) | 2018-11-20 | 2021-09-29 | Abbvie Inc. | Methods for treating acute hcv |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9394279B2 (en) | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
EA023009B1 (ru) | 2010-09-21 | 2016-04-29 | Энанта Фармасьютикалз, Инк. | Ингибитор hcv сериновой протеазы, полученный из макроциклического пролина, и фармацевтическая композиция, предназначенная для лечения вирусной инфекции |
EP2583680A3 (en) | 2011-10-21 | 2013-06-12 | Abbvie Inc. | Mono (PSI-7977) or combination treatment of DAAs for use in treating HCV |
RU2665365C2 (ru) * | 2012-09-18 | 2018-08-29 | Эббви Инк. | Способы лечения гепатита с |
AU2013318309A1 (en) * | 2012-09-18 | 2015-04-02 | Abbvie Inc. | Methods for treating hepatitis C |
LT2968301T (lt) * | 2013-03-14 | 2017-05-25 | Abbvie Inc. | Dviejų antivirusinių vaistų derinys, skirtas hepatito c gydymui |
US20150119400A1 (en) * | 2013-10-25 | 2015-04-30 | Abbvie, Inc. | Methods for treating hcv |
CN110302361A (zh) * | 2014-04-02 | 2019-10-08 | 艾伯维公司 | 治疗hcv的方法 |
-
2016
- 2016-07-07 BR BR112018000383A patent/BR112018000383A2/pt not_active Application Discontinuation
- 2016-07-07 JP JP2017568145A patent/JP6808660B2/ja active Active
- 2016-07-07 MX MX2018000240A patent/MX2018000240A/es unknown
- 2016-07-07 CN CN201680051535.9A patent/CN107921038A/zh active Pending
- 2016-07-07 EP EP16741468.9A patent/EP3319604A1/en not_active Withdrawn
- 2016-07-07 CA CA2991417A patent/CA2991417A1/en not_active Abandoned
- 2016-07-07 WO PCT/US2016/041334 patent/WO2017007934A1/en active Application Filing
- 2016-07-07 AU AU2016291154A patent/AU2016291154B2/en active Active
- 2016-07-07 US US15/738,773 patent/US20180177779A1/en not_active Abandoned
-
2018
- 2018-11-15 HK HK18114657.5A patent/HK1255481A1/zh unknown
-
2020
- 2020-12-08 JP JP2020203169A patent/JP2021050223A/ja active Pending
-
2024
- 2024-03-22 US US18/613,308 patent/US20240232171A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20180177779A1 (en) | 2018-06-28 |
JP2018519321A (ja) | 2018-07-19 |
BR112018000383A2 (pt) | 2018-09-18 |
EP3319604A1 (en) | 2018-05-16 |
CN107921038A (zh) | 2018-04-17 |
AU2016291154B2 (en) | 2021-10-21 |
MX2018000240A (es) | 2018-03-14 |
US20240232171A1 (en) | 2024-07-11 |
CA2991417A1 (en) | 2017-01-12 |
JP2021050223A (ja) | 2021-04-01 |
WO2017007934A1 (en) | 2017-01-12 |
AU2016291154A1 (en) | 2018-01-25 |
JP6808660B2 (ja) | 2021-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI3785717T1 (sl) | Postopki za zdravljenje okužb s Coronaviridae | |
HK1244217A1 (zh) | 用於治療蛋白質病的方法 | |
GB201500989D0 (en) | Process | |
GB201502894D0 (en) | Process | |
GB201502893D0 (en) | Process | |
GB201505311D0 (en) | Process | |
HK1248133A1 (zh) | 治療神經母細胞瘤的方法 | |
HK1255481A1 (zh) | 用於治療hcv的方法 | |
GB201506572D0 (en) | Process | |
GB201501952D0 (en) | Process | |
GB201507170D0 (en) | Process | |
GB201501953D0 (en) | Process | |
GB201503635D0 (en) | Process | |
GB201500990D0 (en) | Process | |
GB201504948D0 (en) | Process | |
GB201502814D0 (en) | Process | |
GB201501423D0 (en) | Process | |
GB201503607D0 (en) | Process | |
IL254336A0 (en) | A new treatment method | |
ZA201607068B (en) | Methods for treating hypersomnia | |
PT3250218T (pt) | Péptido natkide para o tratamento da obesidade | |
GB201506536D0 (en) | Process | |
GB201505981D0 (en) | Process | |
GB201505712D0 (en) | Process | |
EP3313398A4 (en) | METHODS OF TREATING HCV |